ProKidney Q2 2026 loss $46.4M, cash $181.6M; PROACT 1 interim enrollment complete

PROKIDNEY CORP.

Completed enrollment for PROACT 1 accelerated approval analysis (~320 pts); topline eGFR slope results expected Q2 2027.
Full enrollment of ~470 patients on track for H2 2026; confirmatory results anticipated H2 2029.
Appointed Kenneth Locke as CTO in June 2026; 25+ years R&D/CMC/supply chain experience.
Cash and equivalents $181.6M at June 30, 2026, down from $224.9M at March 31, 2026; supports ops into mid-2027.
Net loss before noncontrolling interest $46.4M in Q2 2026 vs $37.0M in Q2 2025; R&D expenses rose to $36.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.